GT201300235A - Uso de 2,3-dihidroimidazo (1,2-c) quinazolinas sustituidas - Google Patents
Uso de 2,3-dihidroimidazo (1,2-c) quinazolinas sustituidasInfo
- Publication number
- GT201300235A GT201300235A GT201300235A GT201300235A GT201300235A GT 201300235 A GT201300235 A GT 201300235A GT 201300235 A GT201300235 A GT 201300235A GT 201300235 A GT201300235 A GT 201300235A GT 201300235 A GT201300235 A GT 201300235A
- Authority
- GT
- Guatemala
- Prior art keywords
- compound
- pharmaceutical composition
- expression
- composition containing
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
Abstract
- USO DE UN COMPUESTO DE 2,3-DIHIDROIMIDAZO[1,2-C]QUINAZOLINA, O DE UNA COMPOSICIÓN FARMACÉUTICA QUE CONTIENE EL MISMO, COMO AGENTE ACTIVO ÚNICO, O DE UNA COMBINACIÓN DE A) DICHO COMPUESTO O UNA COMPOSICIÓN FARMACÉUTICA QUE CONTIENE DICHO COMPUESTO O UNA COMPOSICIÓN FARMACÉUTICA QUE CONTIENE DICHO COMPUESTO Y B) UNO O MÁS AGENTES ACTIVOS ADICIONALES, PARA LA PREPARACIÓN DE UN MEDICAMENTO PARA EL TRATAMIENTO O PROFILAXIS DE CÁNCER;- COMBINACIONES DE A)DICHO COMPUESTO Y B)UNO O MÁS AGENTES ACTIVOS ADICIONALES;- UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE DICHO COMPUESTO COMO AGENTE ACTIVO ÚNICO PARA EL TRATAMIENTO DE CÁNCER DE MAMA;- UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UNA COMBINACIÓN DE A)DICHO COMPUESTO Y B) UNO O MÁS AGENTES ACTIVOS ADICIONALES;- USODE BIOMARCADORES INVOLUCRADOS EN LA MODIFICACIÓN DE LA EXPRESIÓN DE BCL, EXPRESIÓN Y/O ACTIVACIÓN DE LA FAMILIA HER, SEÑALIZACIÓN POR PIK3CA Y/O PÉRDIDA DE PTEN PARA PREDECIR LA SENSIBILIDAD Y/O RESISTENCIA DE UN PACIENTE CON CÁNCER A DICHO COMPUESTO Y PROVEER UNA COMBINACIÓN SINÉRGICA BASADA EN LA RAZÓN, COMO SE DEFINE EN LA PRESENTE, PARA INCREMENTAR LA SENSIBILIDAD Y/O PARA SUPERAR LA RESISTENCIA; Y- UN MÉTODO PARA DETERMINAR EL NIVEL DE UN COMPONENTE DE UNO O MÁS DE EXPRESIÓN DE BCL, EXPRESIÓN Y/O ACTIVACIÓN DE LA FAMILIA HER, SEÑALIZACIÓN POR PIK3CA Y/O PÉRDIDA DE PTEN.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11161142 | 2011-04-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT201300235A true GT201300235A (es) | 2014-08-27 |
Family
ID=45894478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT201300235A GT201300235A (es) | 2011-04-05 | 2013-10-04 | Uso de 2,3-dihidroimidazo (1,2-c) quinazolinas sustituidas |
Country Status (28)
Country | Link |
---|---|
US (1) | US10202385B2 (es) |
EP (1) | EP2694069A1 (es) |
JP (1) | JP6013446B2 (es) |
KR (1) | KR102006033B1 (es) |
CN (1) | CN103608018B (es) |
AP (1) | AP3751A (es) |
AR (1) | AR088730A1 (es) |
AU (2) | AU2012238887A1 (es) |
BR (1) | BR112013025517A2 (es) |
CA (1) | CA2832120C (es) |
CL (1) | CL2013002869A1 (es) |
CU (1) | CU24349B1 (es) |
DO (1) | DOP2013000224A (es) |
EA (1) | EA027670B1 (es) |
EC (1) | ECSP13013007A (es) |
GT (1) | GT201300235A (es) |
IL (1) | IL228435A0 (es) |
JO (1) | JO3733B1 (es) |
MA (1) | MA35015B1 (es) |
MX (1) | MX2013011582A (es) |
MY (1) | MY169532A (es) |
PE (1) | PE20140571A1 (es) |
SG (1) | SG193577A1 (es) |
TN (1) | TN2013000402A1 (es) |
TW (1) | TWI639599B (es) |
UA (1) | UA114177C2 (es) |
UY (1) | UY33984A (es) |
WO (1) | WO2012136549A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
SG187425A1 (en) | 2008-01-04 | 2013-02-28 | Intellikine Llc | Certain chemical entities, compositions and methods |
EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
ES2637113T3 (es) | 2011-01-10 | 2017-10-10 | Infinity Pharmaceuticals, Inc. | Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas |
EP2508525A1 (en) * | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
CU24400B1 (es) | 2013-04-08 | 2019-04-04 | Bayer Pharma AG | Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas |
WO2015082376A2 (en) * | 2013-12-03 | 2015-06-11 | Bayer Pharma Aktiengesellschaft | Use of pi3k-inhibitors |
US20150320755A1 (en) * | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
EP3018127A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
WO2016087490A1 (en) * | 2014-12-03 | 2016-06-09 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
KR101665234B1 (ko) * | 2015-02-10 | 2016-10-12 | 순천향대학교 산학협력단 | 골손실의 완화, 예방 또는 치료용 약학적 조성물 및 건강기능식품 |
EP3268490B1 (en) | 2015-03-09 | 2020-07-08 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations |
JP6935415B2 (ja) | 2016-03-08 | 2021-09-15 | バイエル ファーマ アクチエンゲゼルシャフト | 2−アミノ−N−[7−メトキシ−2,3−ジヒドロイミダゾ−[1,2−c]キナゾリン−5−イル]ピリミジン−5−カルボキサミド類 |
AU2017281797A1 (en) | 2016-06-24 | 2019-01-24 | Infinity Pharmaceuticals, Inc. | Combination therapies |
EP3515911A1 (en) | 2016-09-23 | 2019-07-31 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
WO2019002068A1 (en) | 2017-06-28 | 2019-01-03 | Bayer Consumer Care Ag | COMBINATION OF A PI3K INHIBITOR AND AN ANDROGEN RECEPTOR ANTAGONIST |
US20210187134A1 (en) * | 2018-08-28 | 2021-06-24 | Bayer As | Combination of pi3k-inhibitors and targeted thorium conjugates |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1400959A (en) | 1919-04-26 | 1921-12-20 | Ste Chim Usines Rhone | Process and apparatus for carrying out chemical reactions by catalysis |
US1539891A (en) | 1920-08-09 | 1925-06-02 | Harry A Lewis | Magnetic lifting device |
US1450048A (en) | 1921-09-24 | 1923-03-27 | Mary S Patterson | Nut lock |
BE397809A (es) | 1932-08-25 | |||
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
US20040247662A1 (en) | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
US20040180846A1 (en) * | 2001-03-01 | 2004-09-16 | Ruo-Pan Huang | Connexin enhances chemotherapy-induced apoptiosis in human cancer cells inhibiting tumor cell proliferation |
JP2005532070A (ja) * | 2002-07-03 | 2005-10-27 | ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | Mda−7媒介型アポトーシスの調節因子の同定方法 |
RU2326881C9 (ru) | 2002-09-30 | 2009-04-10 | Байер Фармасьютикалс Корпорейшн | Конденсированные производные азолпиримидина, обладающие свойствами ингибитора фосфатидилинозитол-3-киназы (pi3k) |
RU2318500C2 (ru) * | 2005-10-18 | 2008-03-10 | Общество С Ограниченной Ответственностью "Митотехнология" | Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели |
JP5190233B2 (ja) | 2006-09-01 | 2013-04-24 | パナソニック株式会社 | 無線通信装置 |
AR064106A1 (es) | 2006-12-05 | 2009-03-11 | Bayer Schering Pharma Ag | Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis |
US20090098118A1 (en) * | 2007-10-15 | 2009-04-16 | Thomas Friess | Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
JP5620275B2 (ja) * | 2008-01-14 | 2014-11-05 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 超増殖性疾患及び脈管形成に関連する疾病を処理するために有用なスルホン置換された2,3−ジヒドロイミダゾ[1,2−c]キナゾリン誘導体類 |
WO2009126172A1 (en) * | 2008-04-11 | 2009-10-15 | The Trustees Of Columbia University In The City Of New York | Resistance to polyphenon e due to increased bcl-2 expression |
US8258329B2 (en) | 2008-04-18 | 2012-09-04 | Reata Pharmaceuticals, Inc. | Dehydroandrosterone analogs including an anti-inflammatory pharmacore and methods of use |
US8071315B2 (en) * | 2008-04-30 | 2011-12-06 | Sanford-Burnham Medical Research Institute | Detecting Bcl-B expression in cancer and uses thereof |
FR2932483A1 (fr) * | 2008-06-13 | 2009-12-18 | Cytomics Systems | Composes utiles pour le traitement des cancers. |
US8128386B2 (en) | 2008-06-26 | 2012-03-06 | Hamilton Sundstrand Corporation | Variable flow pumping system |
EP2168582A1 (en) * | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
EP2168583A1 (en) * | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
JP5336306B2 (ja) | 2008-10-20 | 2013-11-06 | 信越化学工業株式会社 | レジスト下層膜形成方法、これを用いたパターン形成方法、及びレジスト下層膜材料 |
NZ596366A (en) | 2009-05-14 | 2013-12-20 | Bayer Ip Gmbh | Enhanced immune response in avian species |
PE20130191A1 (es) * | 2010-04-16 | 2013-02-21 | Bayer Ip Gmbh | Combinaciones que contienen 2, 3-dihidroimidazo[1, 2-c]quinazolina sustituida |
UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
UA113280C2 (xx) | 2010-11-11 | 2017-01-10 | АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ | |
CN103501810A (zh) | 2010-12-22 | 2014-01-08 | 拜耳知识产权有限责任公司 | 牛物种中增强的免疫应答 |
EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
CN104661846B (zh) | 2012-09-21 | 2017-03-22 | 丰田自动车株式会社 | 混合动力车辆用驱动装置 |
-
2012
- 2012-03-27 JO JOP/2012/0065A patent/JO3733B1/ar active
- 2012-03-28 AR ARP120101035A patent/AR088730A1/es active Pending
- 2012-03-28 UY UY0001033984A patent/UY33984A/es not_active Application Discontinuation
- 2012-03-28 TW TW101110917A patent/TWI639599B/zh not_active IP Right Cessation
- 2012-03-29 AP AP2013007147A patent/AP3751A/en active
- 2012-03-29 MY MYPI2013701876A patent/MY169532A/en unknown
- 2012-03-29 PE PE2013002187A patent/PE20140571A1/es not_active Application Discontinuation
- 2012-03-29 CN CN201280027514.5A patent/CN103608018B/zh not_active Expired - Fee Related
- 2012-03-29 AU AU2012238887A patent/AU2012238887A1/en not_active Abandoned
- 2012-03-29 UA UAA201312764A patent/UA114177C2/uk unknown
- 2012-03-29 US US14/009,751 patent/US10202385B2/en active Active
- 2012-03-29 CU CUP2013000134A patent/CU24349B1/es unknown
- 2012-03-29 EA EA201301106A patent/EA027670B1/ru not_active IP Right Cessation
- 2012-03-29 WO PCT/EP2012/055595 patent/WO2012136549A1/en active Application Filing
- 2012-03-29 KR KR1020137028953A patent/KR102006033B1/ko active IP Right Grant
- 2012-03-29 EP EP12710955.1A patent/EP2694069A1/en not_active Withdrawn
- 2012-03-29 SG SG2013071121A patent/SG193577A1/en unknown
- 2012-03-29 JP JP2014503077A patent/JP6013446B2/ja not_active Expired - Fee Related
- 2012-03-29 MX MX2013011582A patent/MX2013011582A/es unknown
- 2012-03-29 MA MA36289A patent/MA35015B1/fr unknown
- 2012-03-29 CA CA2832120A patent/CA2832120C/en active Active
- 2012-03-29 BR BR112013025517A patent/BR112013025517A2/pt not_active Application Discontinuation
-
2013
- 2013-09-15 IL IL228435A patent/IL228435A0/en unknown
- 2013-10-03 TN TNP2013000402A patent/TN2013000402A1/fr unknown
- 2013-10-04 CL CL2013002869A patent/CL2013002869A1/es unknown
- 2013-10-04 GT GT201300235A patent/GT201300235A/es unknown
- 2013-10-04 DO DO2013000224A patent/DOP2013000224A/es unknown
- 2013-11-04 EC ECSP13013007 patent/ECSP13013007A/es unknown
-
2017
- 2017-05-24 AU AU2017203474A patent/AU2017203474B2/en not_active Ceased
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT201300235A (es) | Uso de 2,3-dihidroimidazo (1,2-c) quinazolinas sustituidas | |
ES2649340T3 (es) | Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer | |
HRP20160427T1 (hr) | Fitokanabinoidi u liječenju raka | |
CR20150523A (es) | Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas | |
BR112013027119A2 (pt) | novos conjugados ligante-droga (adcs) e uso dos mesmos | |
CL2013002005A1 (es) | Compuesto 8-[5-(1-hidroxi-1-metiletil)piridin-3-il]-1-[(2s)-2-metoxipropil]-3-metil-1,3-dihidro-2h-imidazo[4,5-c]quinazolin-2-ona; inhibidor pi3k y como mtor; composicion farmaceutica que lo comprende; combinacion farmceutica; y su uso en el tratamiento del cancer. | |
NZ749217A (en) | Androgen receptor modulator and uses thereof | |
CL2012002326A1 (es) | Uso de una combinación de por lo menos un agente quimioterapéutico y una cantidad efectiva de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular), porque sirve para preparar un medicamento útil en el tratamiento de cáncer ovárico; y su kit para tratar el cáncer ovárico sin tratamiento anterior en una paciente humana. | |
NZ719520A (en) | Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway | |
ECSP13012618A (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis | |
AR108021A1 (es) | Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3 | |
UY33396A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
MX2011007589A (es) | Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20. | |
GT201100118A (es) | Compuestos de arilo con sustituyentes heterocíclicos como inhibidores hif | |
CL2013000718A1 (es) | Un complejo de inclusion que comprende a) una ciclodextrina, b) fulvestrant y c) un portador; su metodo de preparacion; formulacion y forma de dosificacion que comprende al complejo; preparacion que comprende al complejo o a la formulación; y su uso en el tratamiento del cancer y lupus eritematoso sistemico, entre otras enfermedades. | |
MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
BR112012022243A8 (pt) | Uso de um inibidor de autofagia baseado em tioxantona e de um composto indutor de autofagia para terapia de câncer, composição farmacêutica e kit farmacêutico | |
MX2020014208A (es) | Agentes terapeuticos para administracion subcutanea optimizados. | |
CL2014001959A1 (es) | Compuestos derivados de fenil-1h-imidazo[1,2-b]pirazol sustituidos; procedimiento de preparacion; composicion farmaceutica; y el uso en el tratamiento del cancer. | |
BR112013033544A2 (pt) | dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos | |
CO6761366A2 (es) | Composiciones farmacéuticas para el tratamiento de glioma maligno | |
GB201105050D0 (en) | Pharmaceutical agent | |
WO2013096335A8 (en) | ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT | |
PL414785A1 (pl) | Kwas 3-dodecylosulfanylomasłowy do zastosowania jako lek, zwłaszcza do zapobiegania rozwojowi insulinooporności oraz kompozycja farmaceutyczna zawierająca kwas 3-dodecylosulfanylomasłowy jako substancję czynną |